{"schema_version":"secwatch.filing_event.v1","accession":"0001129928-26-000041","form_type":"8-K","ticker":"ONCY","cik":"0001129928","company_name":"ONCOLYTICS BIOTECH INC","filed_at":"2026-06-16T13:05:18+00:00","discovered_at":"2026-06-16T13:06:00.426760+00:00","generated_at":"2026-06-16T13:06:21.385358+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Oncolytics secures new U.S. patent for pelareorep manufacturing through 2044; method-of-use app to 2046","bullets":["USPTO issued patent covering pelareorep manufacturing process, expected protection into 2044.","Previously filed method-of-use patent application under review, if issued would protect into 2046.","Company plans additional patent filings in 2026 to expand IP across therapeutic applications and combinations.","CEO states patent supports commercial-scale production and long-term value of pelareorep."],"urls":{"canonical":"https://secwatch.observer/filing/0001129928-26-000041","json":"https://secwatch.observer/filing/0001129928-26-000041.json","markdown":"https://secwatch.observer/filing/0001129928-26-000041.md","text":"https://secwatch.observer/filing/0001129928-26-000041.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1129928/000112992826000041/0001129928-26-000041-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1129928/000112992826000041/oncy-20260616.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-16T13:06:21.385358+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}